On November 13th 2014, the Icotinib Hydrochloride Tablets developed and produced by Betta Pharmaceuticals Co., Ltd. was approved by China Food and Drug Administration to be used in first-line treatment of patients with advanced-stage NSCLC with EGFR mutation (Approval No.: 2014B02155). The approval of the indication will provide a new treatment option for many patients suffering from lung cancer in China.

　　The approval of this new indication advanced icotinib’s application from the second, third-line treatment to the first-line and will aim to benefit more patients as early as possible, especially NSCLC patients with EGFR mutation. Not only does it meet the personalized treatment demands of more patients, it also provides suitable lung cancer patients with a more optimized treatment option.